SCR-LIP-000537 · Claim · machine-readable JSON →

In a case series of 24 patients and a narrative review (>1,500 patients), liposuction (TLAL, VASER, WAL) reduced spontaneous pain (VAS 7.10→2.00), edema (8.50→2.10), and conservative-therapy needs, with benefits sustained up to 12 years, but stage I-II patients reduced CDT needs more than stage III (50% vs 16.7%, p=0.0019), framing it as symptom management when conservative therapy fails rather than a cure.

This single-paper claim was consolidated into general propositions (R-CLM-19); its evidence now sits under:

Claim at a glance
Type
clinical association
Knowledge state
Emerging
Evidence certainty
low (GRADE)
Evidence
1 source(s)
Dates
2026-11-17 → 2026-11-17

Structured evidence, machine-compiled — not a verdict.

Auto-compiled by the Layer 1 surveillance loop; not yet human-reviewed. anthropic/claude-opus-4.8 · 2026-11-17

Evidence over time

2024Outcomes of liposuction techniques for management of lipedema: a case series and narrative review (2024) · refining

Evidence (1)

Context (PECO)

Populationpatients with lipedema, stage I-III (n=24 case series + review)
Conditionlipedema
Exposureliposuction (tumescent/TLAL, VASER, WAL)
Comparatorpre- vs post-operative; conservative therapy; between techniques
Outcomepain, edema, QoL (VAS/Likert), reduction in conservative-therapy needs, long-term durability
Scopeauto-ingested from Layer 1 surveillance

Answers these questions

Gaps & caveats

Auto-ingested single source; not yet human-reviewed.

Change log